Advertisement
Advertisement
GANX
Gain Therapeutics, Inc. Common Stock
1.08
USDSponsored
-0.01
-0.92%
Nov 10, 15:59 UTC -5
Closed
After-Market
1.13
+0.05
+4.35%
Gain Therapeutics, Inc. Common Stock (GANX) Earnings
GANX Earnings Reports
Positive Surprise Ratio
GANX beat 13 of 22 last estimates.
59%
Next Report
Date of Next Report
Nov 18, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.13
Implied change from Q2 26 (Revenue/ EPS)
--
/+18.18%
Implied change from Q3 25 (Revenue/ EPS)
--
/-13.33%
Gain Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 11, 2026, GANX reported earnings of -0.11 USD per share (EPS) for Q2 26, beating the estimate of -0.14 USD, resulting in a 24.03% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +16.38% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of -0.13 USD, with revenue projected to reach -- USD, implying an increase of 18.18% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Definium Therapeutics, Inc. Common Shares
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$0.56
Actual
-$0.46
Surprise
+19.06%
Ocular Therapeutix, Inc.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.42
Surprise
-13.54%
Harrow, Inc. Common Stock
Report Date
Nov 09, 2026 For Q3 26
Estimate
$0.22
Actual
$0.12
Surprise
-45.92%
SIGA Technologies Inc.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-Actual
-$0.04
Surprise
-
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
Minerva Neurosciences, Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.12
Actual
$1.94
Surprise
+1,629.97%
Tonix Pharmaceuticals Holding Corp.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$2.40
Actual
-$2.89
Surprise
-20.23%
Cumberland Pharmaceuticals Inc
Report Date
Nov 10, 2026 For Q3 26
Estimate
-Actual
-$0.07
Surprise
-
PMV Pharmaceuticals, Inc
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Corbus Pharmaceuticals Holdings, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$1.23
Actual
-$1.81
Surprise
-46.07%
FAQ
What were Gain Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Gain Therapeutics, Inc. Common Stock reported EPS of -$0.11, beating estimates by 24.03%, and revenue of $0.00, 0% as expectations.
How did the market react to Gain Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 16.38%, changed from $1.77 before the earnings release to $2.06 the day after.
When is Gain Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 18, 2026.
What are the forecasts for Gain Therapeutics, Inc. Common Stock's next earnings report?
Based on 6
analysts, Gain Therapeutics, Inc. Common Stock is expected to report EPS of -$0.13 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.